Meta-analysis of urinary C-terminal telopeptide of type II collagen as a biomarker in osteoarthritis diagnosis

Mingjian Huang, Jingyu Zhao, Yan Huang, Liming Dai, Xiaoling Zhang, Mingjian Huang, Jingyu Zhao, Yan Huang, Liming Dai, Xiaoling Zhang

Abstract

Objective: This study aims to discover that the urinary C-terminal telopeptide of type II collagen (uCTX-II) levels differ between osteoarthritis (OA) patients and healthy individuals (controls). According to this difference, we may conclude that uCTX-II can be a biomarker for OA diagnosis.

Methods: We searched MEDLINE and EMBASE databases updated to 2014 to find literature on OA biomarkers. We retrieved the publications that met the required criterion. Literature quality was assessed according to the Newcastle-Ottawa Scale. Publication bias was assessed by Begg's test and Egger's test with the software STATA version 12.0. The weighted mean difference (WMD) was calculated, and the subgroup analysis was completed using STATA 12.0.

Results: Six publications were included in our analysis. The WMD for OA patients versus the controls was 83.05, which was within the 95% confidence interval. For subgroup analysis, the WMD of patients with severe OA was 119.92, whereas that of patients with mild OA was 28.07.

Conclusions: uCTX-II levels were higher in OA patients than in controls, subgroup analysis revealed that the uCTX-II levels rised with the OA severity, the heterogeneity originated from different levels of OA severity, These results showed that uCTX-II would be a promising clinical biomarker in OA diagnosis.

Keywords: biomarkers; osteoarthritis; urinary C-terminal telopeptide of type II collagen.

Figures

Scheme 1
Scheme 1
Flow diagram of literature search.
Figure 1
Figure 1
Forest plot of the weighted mean difference of urinary C-terminal telopeptide of type II collagen in patients with radiographically diagnosed osteoarthritis compared with controls. CI = confidence interval; WMD = weighted mean difference.
Figure 2
Figure 2
Funnel plot to assess the publication bias. WMD = weighted mean difference.
Scheme 2
Scheme 2
Begg's test and Egger's test to confirm the publication bias.
Figure 3
Figure 3
Forest plot of the weighted mean difference of urinary C-terminal telopeptide of type II collagen in patients with different severity of osteoarthritis. CI = confidence interval; KL = Kellgren–Lawrence; WMD = weighted mean difference.
Figure 4
Figure 4
Forest plot of the weighted mean difference of urinary C-terminal telopeptide of type II collagen in osteoarthritis patients of different sexes. CI = confidence interval; WMD = weighted mean difference.

References

    1. Goldring M.B., Goldring S.R. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci. 2010;1192:230–237.
    1. Sinusas K. Osteoarthritis: diagnosis and treatment. Am Fam Physician. 2012;85:49–56.
    1. Lotz M., Martel-Pelletier J., Christiansen C., Brandi M.L., Bruyere O., Chapurlat R. Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis. 2013;72:1756–1763.
    1. van Spil W.E., DeGroot J., Lems W.F., Oostveen J.C., Lafeber F.P. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthritis Cartilage. 2010;18:605–612.
    1. Bauer D.C., Hunter D.J., Abramson S.B., Attur M., Corr M., Felson D. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage. 2006;14:723–727.
    1. Dam E.B., Loog M., Christiansen C., Byrjalsen I., Folkesson J., Nielsen M. Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers. Arthritis Res Ther. 2009;11:R115.
    1. Reijman M., Hazes J.M., Bierma-Zeinstra S.M., Koes B.W., Christgau S., Christiansen C. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum. 2004;50:2471–2478.
    1. Sowers M.F., Karvonen-Gutierrez C.A., Yosef M., Jannausch M., Jiang Y., Garnero P. Longitudinal changes of serum COMP and urinary CTX-II predict X-ray defined knee osteoarthritis severity and stiffness in women. Osteoarthritis Cartilage. 2009;17:1609–1614.
    1. Tanishi N., Yamagiwa H., Hayami T., Mera H., Koga Y., Omori G. Relationship between radiological knee osteoarthritis and biochemical markers of cartilage and bone degradation (urine CTX-II and NTX-I): the Matsudai Knee Osteoarthritis Survey. J Bone Miner Metab. 2009;27:605–612.
    1. Poonpet T., Honsawek S. Adipokines: biomarkers for osteoarthritis? World J Orthop. 2014;5:319–327.
    1. Dam E.B., Byrjalsen I., Karsdal M.A., Qvist P., Christiansen C. Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis Cartilage. 2009;17:384–389.
    1. Garnero P., Charni N., Juillet F., Conrozier T., Vignon E. Increased urinary type II collagen helical and C telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis. Ann Rheum Dis. 2006;65:1639–1644.
    1. Garnero P., Piperno M., Gineyts E., Christgau S., Delmas P.D., Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis. 2001;60:619–626.
    1. Kalai E., Bahlous A., Charni N., Bouzid K., Sahli H., Laadhar L. Association of serum levels of aggrecan ARGS, NITEGE fragments and radiologic knee osteoarthritis in Tunisian patients. Joint Bone Spine. 2012;79:610–615.
    1. Castaneda S., Roman-Blas J.A., Largo R., Herrero-Beaumont G. Osteoarthritis: a progressive disease with changing phenotypes. Rheumatology. 2014;53:1–3.
    1. Garnero P., Ayral X., Rousseau J.C., Christgau S., Sandell L.J., Dougados M. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum. 2002;46:2613–2624.
    1. Garnero P., Conrozier T., Christgau S., Mathieu P., Delmas P.D., Vignon E. Urinary type II collagen C-telopeptide levels are increased in patients with rapidly destructive hip osteoarthritis. Ann Rheum Dis. 2003;62:939–943.
    1. Jung M., Christgau S., Lukoschek M., Henriksen D., Richter W. Increased urinary concentration of collagen type II C-telopeptide fragments in patients with osteoarthritis. Pathobiology. 2004;71:70–76.
    1. Rousseau J.C., Chevrel G., Schott A.M., Garnero P. Increased cartilage type II collagen degradation in patients with osteogenesis imperfecta used as a human model of bone type I collagen alterations. Bone. 2010;46:897–900.
    1. Bruyere O., Collette J., Kothari M., Zaim S., White D., Genant H. Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study. Ann Rheum Dis. 2006;65:1050–1054.
    1. Bay-Jensen A.C., Tabassi N.C., Sondergaard L.V., Andersen T.L., Dagnaes-Hansen F., Garnero P. The response to oestrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique compared with other markers of collagen turnover. Arthritis Res Ther. 2009;11:R9.
    1. Meulenbelt I., Kloppenburg M., Kroon H.M., Houwing-Duistermaat J.J., Garnero P., Hellio-Le Graverand M.P. Clusters of biochemical markers are associated with radiographic subtypes of osteoarthritis (OA) in subject with familial OA at multiple sites. The GARP study. Osteoarthritis Cartilage. 2007;15:379–385.
    1. Catterall J.B., Hsueh M.F., Stabler T.V., McCudden C.R., Bolognesi M., Zura R. Protein modification by deamidation indicates variations in joint extracellular matrix turnover. J Biol Chem. 2012;287:4640–4651.
    1. Onnerfjord P., Khabut A., Reinholt F.P., Svensson O., Heinegard D. Quantitative proteomic analysis of eight cartilaginous tissues reveals characteristic differences as well as similarities between subgroups. J Biol Chem. 2012;287:18913–18924.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel